# Pharmacokinetics, Efficacy and Safety of an Octreotide Implant in Patients With Carcinoid Syndrome

> **NCT00884715** · PHASE1,PHASE2 · TERMINATED · sponsor: **Endo Pharmaceuticals** · enrollment: 10 (actual)

## Conditions studied

- Carcinoid Syndrome

## Interventions

- **DRUG:** Octreotide

## Key facts

- **NCT ID:** NCT00884715
- **Lead sponsor:** Endo Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-07
- **Primary completion:** 2011-11
- **Final completion:** 2011-12
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Program was terminated for business reasons
- **Last updated:** 2013-09-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00884715

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00884715, "Pharmacokinetics, Efficacy and Safety of an Octreotide Implant in Patients With Carcinoid Syndrome". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00884715. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*